Skip to content

HORIZONFP7H2020

Fundacion de la Comunidad Valenciana Centro de Investigacion Principefelipe

Country
ESSpain
Projects
25
As coordinator
7
EU contribution (CORDIS)
EUR 8,785,057
Active
2008 to 2025

Projects

25 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
NanoBiCarNanoBiCar: A novel immunotherapy for infectious diseasesHORIZON2025Third partyNot stated
IMPULSEIMProving User experience, Long-term sustainability and Services of EU-OPENSCREENHORIZON2024ParticipantEUR 91,820
AFRODITAAdvancing Fertility and Reproduction thrOugh Dedicated and Innovative Technological ApplicationsHORIZON2024Associated partnerEUR 0
NATPRIMEEffective Delivery of Nucleic Acid Therapeutics via Designed NanocarriersHORIZON2024ParticipantEUR 503,942
EDC-MASLDInvestigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver diseaseHORIZON2024ParticipantEUR 458,900
REGUBIOMETranscriptional REGUlation as a mediator of bacterial interactions in the microBIOMEHORIZON2023CoordinatorEUR 1,496,479
MultiSMARTMulti-component Soft Materials Advanced Research Training NetworkHORIZON2023ParticipantEUR 251,971
TherACCageTherapeutic Artificial Cells based on Molecular Cages for Glioblastoma TreatmentHORIZON2023Associated partnerEUR 0
POLYBRAINTVersatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.HORIZON2022CoordinatorEUR 150,000
RISEUPRegeneration of Injured Spinal cord by Electro pUlsed bio-hybrid imPlantH20202021ParticipantEUR 508,185
BIOMOLMACSMolecular Machines Functioning in CellsH20202020ParticipantEUR 250,905
POLYMMUNEOff-the-Shelf Polypeptide-based Immunotherapy for Advanced Melanoma TreatmentH20202019CoordinatorEUR 149,938
EU-OPENSCREEN-DRIVEEnsuring long-term sustainability of excellence in chemical biology within Europe and beyondH20202019ParticipantEUR 81,125
EPICExploiting Protein Complexes that Induce Cell-deathH20202016ParticipantEUR 27,000
StemBATNew players in human BAT differentiation and activation: a human PSC-derived BAT approach combined with state of the art genome engineering and –omics based methodologiesH20202016ParticipantEUR 346,869
MyNanoTowards the design of Personalised Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer PatientsH20202015CoordinatorEUR 1,724,169
DEANNDeveloping an European American NGS NetworkH20202014CoordinatorEUR 216,300
MLPM2012Machine Learning for Personalized MedicineFP72013ParticipantEUR 234,949
STATegraUser-driven Development of Statistical Methods for Experimental Planning, Data Gathering, and Integrative Analysis of Next Generation Sequencing, Proteomics and Metabolomics dataFP72012CoordinatorEUR 575,819
EUROCONDOREuropean Consortium for the Early Treatment of Diabetic RetinopathyFP72012ParticipantEUR 76,124

The country is the one the source records for the organisation’s registration (its PIC). A body with sites in several countries is recorded under one of them, which is not always its legal seat: the Spanish research council CSIC, for example, appears under Italy. The data holds no country per site, so we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.